Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

ese and other risks are described in greater detail in our Annual Report on Form 10-K for the year ended December 31, 2007, and our other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward looking statements because of these uncertainties, and the inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. We assume no obligation to update forward looking statements. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

FOLD -G

Table 1

Amicus Therapeutics, Inc.

(a development stage company)

Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share amounts)

Period

from

February 4,

2002

(inception)

Three Months to

Ended March 31, March 31,

2007 2008 2008

Revenue:

Research revenue $- $2,466 $ 3,841

Collaboration revenue - 694 1,103

Total revenue - 3,160 4,944

Operating Expenses:

Research and development 7,085 6,941 96,819

General and administrative 2,850 5,186 43,256

Impairment
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... BOSTON , June 17, 2013 ... $127 billion by 2018, accounting for nearly 16 percent of ... Orphan Drug Report 2013 from Evaluate .   ... to this growing segment of the pharmaceutical industry, Evaluate has ... in-depth, fact-based orphan drug analysis with data fields for integrated ...
(Date:6/17/2013)... 2013 With the huge success of CMO ... Chief Medical Officer Summit for Emerging Life Science Companies on ... in San Francisco on November 4-5, 2013 at the Marines ... West Coast Chief Medical Officers at biotechs have their own ... Director of MPM Capital. Valerie Bowling, Executive Director of The ...
(Date:6/17/2013)... Z Trim Holdings, Inc. (OTC Markets: ... ingredients to a variety of industries, today announced ... application at this year,s annual Institute of Food ... , July 13-16. The Company will demonstrate how ... in meat products thereby helping manufacturers lower costs ...
(Date:6/17/2013)... , June 17, 2013 ... ) has announced the addition of the ... - by Formulations [Liposomes, Microspheres, & Nanoparticles], ... Pen, Needle Free & Auto Injectors] & ... their offering. ,      (Logo: ...
Breaking Biology Technology:Evaluate Launches Enhanced Orphan Drug Intelligence 2Evaluate Launches Enhanced Orphan Drug Intelligence 3Chief Medical Officer Summit for Biotechs Goes West 2Chief Medical Officer Summit for Biotechs Goes West 3Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 2Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 3North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 2North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 3
... adds new line of heart disease and diabetes ... 20 Atherotech, Inc. ... Cholesterol Test in booth #912 at Internal Medicine ... College of Physicians (ACP). The conference takes place ...
... Proof of Mechanism of a Potential Oral Antagonist for ... Amira Pharmaceuticals, Inc., announced today the initiation of ... discovered oral drug candidate for the treatment and control ... acid pathway.AM211 is an oral, selective antagonist of the ...
... Data are New Releases for the Company Building ... Discoveries --DENVER, April 20 DXL625 ... antibodies in their ability to attach and deplete ... research conducted at InNexus Biotechnology Inc. (Toronto Stock ...
Cached Biology Technology:Atherotech to Exhibit its VAP(R) Cholesterol Test at Internal Medicine 2009 in Philadelphia 2Atherotech to Exhibit its VAP(R) Cholesterol Test at Internal Medicine 2009 in Philadelphia 3Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist 2AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies 2AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies 3
(Date:6/14/2013)... the only ones tending their gardens. , At the ... ants cultivate thriving communities of fungi and bacteria using ... are a source of food and shelter for the ... biofuel production. , "We are interested in the whole ... goes in and is converted to energy for the ...
(Date:6/14/2013)... By identifying a protein that acts as a ... have solved the mystery of why some infants are ... and major deformities of the skin and limbs, while ... little or no sign of the illness, called EEC. ... It is rare in its full-blown form, although individual ...
(Date:6/14/2013)... Data presented at EULAR 2013, the Annual Congress of ... biomarkers could significantly improve diagnosis in rheumatoid arthritis (RA). ... and UH-RA.21 were investigated; as a group they ... both early and seronegative disease, with 36% of ... patients testing positive. , RA is a chronic ...
Breaking Biology News(10 mins):Researchers unearth bioenergy potential in leaf-cutter ant communities 2Researchers unearth bioenergy potential in leaf-cutter ant communities 3CSHL geneticists solve mystery of EEC Syndrome's variable severity in children 2CSHL geneticists solve mystery of EEC Syndrome's variable severity in children 3
... The best place to enjoy a breath of fresh air may ... A team of graduating seniors has created a system for public ... lead to tuberculosis (TB), flu and pneumonia. The CityBusters ... Chen, all seniors have installed a $500 device on a ...
... significantly slow the pace of climate change with practical ... bringing successful Western technologies to the developing world, according ... Foreign Affairs . For the last two ... to make progress. Part of the problem, the ...
... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... its first quarter ended March 31, 2012.  Revenues ... of 10% compared to $6.4 million in the same quarter last ... million, or $0.05 per diluted share. These results compared to net ...
Cached Biology News:College students work to sterilize air, kill pathogens on buses 2College students work to sterilize air, kill pathogens on buses 3College students work to sterilize air, kill pathogens on buses 4UCSD researchers: Where international climate policy has failed, grassroots efforts can succeed 2UCSD researchers: Where international climate policy has failed, grassroots efforts can succeed 3UCSD researchers: Where international climate policy has failed, grassroots efforts can succeed 4Aware, Inc. Reports First Quarter 2012 Financial Results 2Aware, Inc. Reports First Quarter 2012 Financial Results 3Aware, Inc. Reports First Quarter 2012 Financial Results 4Aware, Inc. Reports First Quarter 2012 Financial Results 5
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
Adducin beta (C-16)...
This SMAD antibody sampler pack contains 5 Polyclonal ,SMAD antibodies....
Phosphate-Buffered Saline (PBS) 7.4 (1X) liquid...
Biology Products: